Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.40 |
| ▸ | CES2 | O00748 | 1/20 | 0.40 |
| ▸ | CES1 | P23141 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | BTK | Q06187 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.37 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3266445 | 0.81 | POLQ (0.45) | MAPTALDH1A1KMT2AKDM4EMEN1 | |
| SCHEMBL11351438 | 0.81 | GPBAR1 (0.41) | GPBAR1CES2CES1ALDH1A1LTB4R2 | |
| SCHEMBL11209904 | 0.80 | KMT2A (0.52) | ALDH1A1KMT2AMEN1 | |
| SCHEMBL31606583 | 0.80 | GPBAR1 (0.40) | GPBAR1CES2CES1ALDH1A1KMT2A | |
| SCHEMBL2125940 | 0.80 | GPBAR1 (0.40) | GPBAR1CES2CES1ALDH1A1KMT2A | |
| SCHEMBL28746573 | 0.78 | LTB4R2 (0.47) | ALDH1A1KDM4ELTB4R2 | |
| SCHEMBL25733544 | 0.78 | ALDH1A1 (0.47) | MAPTALDH1A1KMT2AKDM4EMEN1 | |
| SCHEMBL8867493 | 0.76 | KMT2A (0.37) | MAPTBTKALDH1A1KMT2AKDM4E | |
| SCHEMBL8867489 | 0.76 | KMT2A (0.37) | MAPTBTKALDH1A1KMT2AKDM4E | |
| SCHEMBL8867496 | 0.76 | KMT2A (0.37) | MAPTBTKALDH1A1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7897788-B2 | Indol-1-yl-acetic acid derivatives | ACTELION PHARMACEUTICAL LTD. (CH) | 2011-03-01 | — | — | US | disclosed |
| EP-1740171-B1 | INDOL-1-YL-ACETIC ACID DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2010-06-09 | — | — | EP | disclosed |
| US-20070208004-A1 | Indol-1-yl-acetic acid derivatives | ACTELION PHARMACEUTICALS, LTD. (CH) | 2007-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208004-A1 | Indol-1-yl-acetic acid derivatives | IDO1, IDO2, AANAT | GPBAR1 1702/4885CES2 3021/4885CES1 1038/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.